Ato drug mechanism of action
Pro Research Analysisby 
Searched over 200M research papers
Arsenic Trioxide (ATO) Drug Mechanism of Action
Multi-Targeted Anticancer Effects of Arsenic Trioxide
Arsenic trioxide (ATO) is widely used in the treatment of acute promyelocytic leukemia (APL) and has shown effectiveness against other cancers. Its mechanism of action is complex and involves multiple cellular targets and pathways. ATO disrupts several physiological processes, especially those related to protein folding and cellular stress responses. One key target is heat shock protein 60 (Hsp60); ATO binds to Hsp60, impairs its protein refolding function, and disrupts its interactions with p53 and survivin, leading to the degradation of these proteins and promoting cancer cell death .
Inhibition of Redox Systems and Induction of Oxidative Stress
ATO irreversibly inhibits thioredoxin reductase (TrxR), a crucial enzyme in the thioredoxin (Trx) system that helps control cell proliferation and survival. This inhibition leads to increased oxidative stress and triggers apoptosis in cancer cells. The effect is enhanced when the glutathione (GSH) system is also compromised, suggesting that ATO’s anticancer activity is closely linked to its ability to disrupt cellular redox balance .
Disruption of Cell Cycle and Signaling Pathways
ATO interferes with cell cycle progression by downregulating the expression of E2F1 and cyclin E, and by stimulating the retinoblastoma protein (pRb). It also affects the phosphorylation of pRb and reduces the activity of PI3K signaling molecules, which are important for cell growth and survival. These actions collectively inhibit the proliferation of leukemia cells and promote apoptosis 68.
Vascular Disruption and Microtubule Depolymerization
ATO acts as a vascular disrupting agent (VDA) in solid tumors by causing acute vascular shutdown and tumor necrosis. It achieves this by reducing the levels of α- and β-tubulin and inhibiting tubulin polymerization, which disrupts the tumor’s blood supply. When combined with other chemotherapeutic agents, ATO enhances antitumor effects through this mechanism .
Clinical Impact and Therapeutic Strategies
ATO induces apoptosis and myeloid differentiation in APL cells, leading to high remission rates with minimal side effects. It is used both as a single agent and in combination with other drugs to improve treatment outcomes in relapsed and newly diagnosed APL patients .
Atorvastatin (ATO) Mechanism of Action in Cancer
Atorvastatin (also abbreviated as ATO in some studies) is primarily known as a cholesterol-lowering drug but has shown anticancer properties. It inhibits cancer cell proliferation, promotes apoptosis, and reduces invasion and metastasis by affecting the epithelial-mesenchymal transition (EMT) and matrix metalloproteinase (MMP) pathways . Atorvastatin also influences gene expression and signaling networks, especially when used in combination with other drugs, leading to synergistic therapeutic effects .
Atovaquone (ATO) Mechanism of Action
Atovaquone (ATO), another drug sharing the ATO abbreviation, is an antimalarial agent repurposed for cancer therapy. It inhibits mitochondrial complex III and, in modified forms, can also target complex I, leading to reduced cancer cell proliferation and altered immunoregulatory functions .
Conclusion
The mechanism of action of ATO drugs varies depending on the specific compound but generally involves targeting multiple cellular pathways to induce cancer cell death. Arsenic trioxide disrupts protein folding, redox systems, cell cycle progression, and tumor vasculature. Atorvastatin and atovaquone, though different in primary use, also show anticancer effects through inhibition of cell proliferation, induction of apoptosis, and disruption of key cellular processes. These multi-targeted actions make ATO drugs valuable in cancer therapy and highlight the importance of understanding their diverse mechanisms for optimizing treatment strategies 1234+5 MORE.
Sources and full results
Most relevant research papers on this topic